Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
Company Details
- Employees
- 27
- Founded
- -
- in****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- appiabio.com
Appia Bio Questions
Appia Bio's website is appiabio.com
Appia Bio's LinkedIn profile is https://www.linkedin.com/company/appiabio
Appia Bio has
27 employees.
View email and phone details for 27
employees at Appia Bio.
Appia Bio's industry is
Biotechnology Research
Appia Bio's top competitors are
Capsida Biotherapeutics,
Acurastem,
Allogene Therapeutics,
Neogene Therapeutics,
Immunitybio, Inc.,
Immunovec,
Theragent Inc,
Kite Pharma,
Immpact Bio,
A2 Biotherapeutics, Inc..
Appia Bio's support email address is info@appiabio.com
Appia Bio's categories are Biotechnology Research
Appia Bio's founding year is 2020
